公开(公告)号：US20170253844A1

公开(公告)日：2017-09-07

申请号：US15449222

申请日：2017-03-03

Applicant: Corning Incorporated

Inventor： Ye Fang ,  Vasiliy Nikolaevich Goral

IPC: C12M1/32 ,  C12N5/00 ,  C12M1/04

CPC classification number: C12M23/12 ,  C12M23/02 ,  C12M23/24

Abstract: A cell culture apparatus has a structure defining a cell culture microwell. The cell culture microwell defines a top aperture and an inner surface and an axis extending through the top aperture. The top aperture defines a top diametric dimension measured perpendicular to the axis and the inner surface defines a first diametric dimension measured perpendicular to the axis at a widest portion of the microwell and a second diametric dimension measured perpendicular to the axis. The second diametric dimension is at a location along the axis farther from the top aperture than a location along the axis of the first diametric dimension. The top diametric dimension is less than the first diametric dimension, and the second diametric dimension is less than the first diametric dimension.

公开(公告)号：US20170226455A1

公开(公告)日：2017-08-10

申请号：US15499370

申请日：2017-04-27

Applicant: Corning Incorporated

Inventor： Ye Fang ,  Ann MeeJin Ferrie ,  Vasiliy Nikolaevich Goral ,  Allison Jean Tanner ,  Qi Wu

IPC: C12M1/32 ,  C12N5/00

CPC classification number: C12M23/12 ,  C12M41/36 ,  C12N5/0062

Abstract: A cell culture apparatus may include a substrate defining a well. The well may define an interior surface, an exterior surface, an upper aperture and a nadir. The substrate may define a thickness between the interior and exterior surfaces that has a thickness proximate the nadir that is greater than or equal to a thickness proximate the upper aperture.

公开(公告)号：US20130316985A1

公开(公告)日：2013-11-28

申请号：US13897886

申请日：2013-05-20

Applicant: CORNING INCORPORATED

Inventor： Huayun Deng ,  Ye Fang

IPC: A61K31/655 ,  A61K31/192 ,  A61K31/235 ,  A61K31/381 ,  A61K31/24 ,  A61K31/175 ,  A61K31/06 ,  A61K31/05 ,  A61K31/055

CPC classification number: A61K31/655 ,  A61K31/05 ,  A61K31/055 ,  A61K31/06 ,  A61K31/175 ,  A61K31/192 ,  A61K31/235 ,  A61K31/24 ,  A61K31/381

Abstract: A pharmaceutical composition including at least one compound of the Formulas (I), (II), or (III), or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, as defined herein. Also disclosed is a method of treatment of diseases which are pathophysiologically related to GPR35, the GPR35-hERG signaling complex, or both, as defined herein.

Abstract translation: 包含式（I），（II）或（III）的至少一种化合物或其药学上可接受的盐，溶剂化物，包合物或前药的药物组合物，如本文所定义。 还公开了治疗与本文定义的GPR35，GPR35-hERG信号传导复合物或两者病理生理学相关的疾病的方法。